Application for production acceptance of zatoribuprofen, a class 3.1 new drug of Asia Pacific pharmaceutical
-
Last Update: 2014-12-02
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Zatoibuprofen was developed jointly by Chemiphar and zeria company in Japan It was first listed in Japan in 1993 It can selectively act on the inflammatory site, but has no effect on the stomach and kidney Compared with the similar drugs such as naproxen and ibuprofen, zatoibuprofen has the characteristics of high efficiency and small side effects on the stomach It is highly praised in Japanese clinical practice Non steroidal anti-inflammatory drugs have been playing a leading role in the treatment of rheumatoid arthritis and rheumatoid arthritis in China, and their sales volume is far higher than that of other drugs At present, there is no production approval for zatobrofen in China According to the public information, there are more than a dozen enterprises applying for zatoribuprofen, but most of them are in the clinical research stage; only three subsidiaries of Asia Pacific pharmaceutical, Dianhong pharmaceutical and Jinling Pharmaceutical (000919.SZ), Nanjing Baijingyu pharmaceutical, are applying for production.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
